361 related articles for article (PubMed ID: 26181017)
1. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
2. History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.
Lindqvist EK; Landgren O; Lund SH; Turesson I; Hultcrantz M; Goldin L; Björkholm M; Kristinsson SY
Ann Hematol; 2017 Feb; 96(2):261-269. PubMed ID: 27807648
[TBL] [Abstract][Full Text] [Related]
3. [Multiple myeloma after monoclonal gammopathy of uncertain significance. Study of 10 patients].
Salgado C; Bladé J; López-Guillermo A; Cervantes F; Montserrat E; Rozman C
Sangre (Barc); 1993 Oct; 38(5):371-4. PubMed ID: 8140498
[TBL] [Abstract][Full Text] [Related]
4. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
[TBL] [Abstract][Full Text] [Related]
5. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
[TBL] [Abstract][Full Text] [Related]
8. [Benign monoclonal gammopathy].
Shirota T; Kondo M; Uchida H; Ito H
Nihon Rinsho; 1995 Mar; 53(3):720-4. PubMed ID: 7699912
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal gammopathy of undetermined significance].
Chaïbi P; Merlin L; Thomas C; Piette F
Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
[TBL] [Abstract][Full Text] [Related]
12. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Srkalovic G; Cameron MG; Rybicki L; Deitcher SR; Kattke-Marchant K; Hussein MA
Cancer; 2004 Aug; 101(3):558-66. PubMed ID: 15274069
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA
Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
[TBL] [Abstract][Full Text] [Related]
15. Fracture risk in monoclonal gammopathy of undetermined significance.
Melton LJ; Rajkumar SV; Khosla S; Achenbach SJ; Oberg AL; Kyle RA
J Bone Miner Res; 2004 Jan; 19(1):25-30. PubMed ID: 14753733
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
Berenson JR; Yellin O
Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382
[TBL] [Abstract][Full Text] [Related]
17. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Zhan F; Barlogie B; Arzoumanian V; Huang Y; Williams DR; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M; Dhodapkar M; Shaughnessy JD
Blood; 2007 Feb; 109(4):1692-700. PubMed ID: 17023574
[TBL] [Abstract][Full Text] [Related]
18. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
[No Abstract] [Full Text] [Related]
19. Monoclonal gammopathies of undetermined significance.
Kyle RA; Rajkumar SV
Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
[TBL] [Abstract][Full Text] [Related]
20. The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS).
Madan S; Greipp PR
Blood Rev; 2009 Nov; 23(6):257-65. PubMed ID: 19699016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
